Aggregate additional revenue recognition milestone method revenue achieved.

No definition available.

Name:	sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueAchieved
Namespace Prefix:	sgmo_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Aggregate additional revenue recognition milestone method revenue eligible to receive.

+ References

No definition available.

+ Details

Name:	sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive
Namespace Prefix:	sgmo_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Aggregate additional revenue recognition milestone method revenue to be recognized.

+ References

No definition available.

+ Details

Name:	sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognized
Namespace Prefix:	sgmo_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Aggregate additional revenue recognition milestone method revenue to be recognized on acceptance of application.

+ References

No definition available.

+ Details

Name:	sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognizedOnAcceptanceOfApplication
Namespace Prefix:	sgmo_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Aggregate number of gene targets.

+ References

No definition available.

+ Details

Name:	sgmo_AggregateNumberOfGeneTargets
Namespace Prefix:	sgmo_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Collaboration and license agreements number of products approved under agreement.

+ References

No definition available.

+ Details

Name:	sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement
Namespace Prefix:	sgmo_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Initial research term of agreement.

+ References

No definition available.

+ Details

Name:	sgmo_InitialResearchTermOfAgreement
Namespace Prefix:	sgmo_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Milestone revenue receivable.

+ References

No definition available.

+ Details

Name:	sgmo_MilestoneRevenueReceivable
Namespace Prefix:	sgmo_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Number of additional gene targets.

+ References

No definition available.

+ Details

Name:	sgmo_NumberOfAdditionalGeneTargets
Namespace Prefix:	sgmo_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of companies jointly conducting research program.

+ References

No definition available.

+ Details

Name:	sgmo_NumberOfCompaniesJointlyConductingResearchProgram
Namespace Prefix:	sgmo_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of gene targets.

+ References

No definition available.

+ Details

Name:	sgmo_NumberOfGeneTargets
Namespace Prefix:	sgmo_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of initial gene targets.

+ References

No definition available.

+ Details

Name:	sgmo_NumberOfInitialGeneTargets
Namespace Prefix:	sgmo_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of licensed products.

+ References

No definition available.

+ Details

Name:	sgmo_NumberOfLicensedProducts
Namespace Prefix:	sgmo_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of research program.

+ References

No definition available.

+ Details

Name:	sgmo_NumberOfResearchProgram
Namespace Prefix:	sgmo_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

+ Details

Name:	us-gaap_DeferredRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 20

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380

+ Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount of consideration recognized during the period for the milestone or milestones.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 28

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=19771982&loc=SL6892177-166501

+ Details

Name:	us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(e))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name:	us-gaap_RoyaltyRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_CounterpartyNameAxis=sgmo_BiogenMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CounterpartyNameAxis=sgmo_ShireAgMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Major Customers, Partnerships and Strategic Alliances - Additional Information (Detail) (USD $)	1 Months Ended	12 Months Ended			0 Months Ended	1 Months Ended		3 Months Ended
	Jan. 31, 2014 Program Company	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2014 Product	Jun. 30, 2012 Targets	Jan. 31, 2012 Targets	Sep. 30, 2014
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Number of companies jointly conducting research program	2
Number of research programs	2sgmo_NumberOfResearchProgram
Research and development		$ 56,744,000us-gaap_ResearchAndDevelopmentExpense	$ 36,979,000us-gaap_ResearchAndDevelopmentExpense	$ 31,709,000us-gaap_ResearchAndDevelopmentExpense
Biogen [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenues under agreement	20,000,000
Potential amount eligible to receive for certain milestones	126,300,000
Potential amount to be funded for achievement of specified commercialized and sales milestones	167,500,000
Milestone revenue receivable	293,800,000
Number of licensed products approved under agreement					0
Research program to develop laboratory research reagents		40 months
Deferred revenue		14,900,000			14,900,000
Biogen [Member] \| Beta-thalassemia [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Milestone revenue receivable	7,500,000
Research and development		5,200,000
Biogen [Member] \| Sickle cell disease [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Milestone revenue receivable	7,500,000
Biogen [Member] \| Other Projects
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and development		3,500,000
Shire AG [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenues under agreement							13,000,000
Potential amount to be funded for achievement of specified commercialized and sales milestones							180,000,000
Milestone revenue receivable							33,500,000
Research program to develop laboratory research reagents		6 years
Deferred revenue		6,800,000			6,800,000
Research and development		21,100,000	14,200,000	7,700,000
Aggregate number of gene targets							7
Number of initial gene targets							4
Number of gene targets						5
Number of additional gene targets						2
IND or CTA submission amount							8,500,000
Potential amount to be funded for certain Shire milestones							213,500,000
Milestone payment		1,000,000						1,000,000
Number of products approved		0
Royalty revenues		$ 0